I-42 Regulation of a hepatitis C virus co-receptor claudin-1 in hepatocytes  by Kojima, T. et al.
S16 Concurrent Sessions
I-42 Regulation of a hepatitis C virus co-receptor
claudin-1 in hepatocytes
T. Kojima1 *, M. Lan2, T. Yamamoto1, M. Murata1,
K.I. Takano3, M. Imamura1,4, S. Son1,4, H. Yamaguchi1,4,
N. Sawada1. 1Departments of Pathology, 3Otolaryngology,
and 4Surgery, Sapporo Medical University School of
Medicine, Sapporo, Japan, 2Department of Pathology,
Beijing Ditan Hospital, Beijing, China
The polarization of hepatocytes involves formation of
functionally distinct sinusoidal (basolateral) and bile
canalicular (apical) plasma membrane domains that are
separated by tight junctions. In murine livers, integral tight
junction proteins claudin-1, -2, -3, -5, -7, -8, -12, -14 which
can form tight junction strands are detected together with
occludin, JAM, CAR and tricellulin, and claudin-1, -2, -3
are expressed in the bile canaliculus region of hepatocytes.
In the livers (mouse, rat, human), claudin-1 and -3 are
expressed in the whole liver lobule, whereas claudin-2 shows
a lobular gradient increasing from periportal to pericentral
hepatocytes. It is reported that downregulation of claudin-1
serves as a potential marker for a poor prognosis in HCC.
More recently, it is found that the claudin-1 is a hepatitis C
virus co-receptor with CD81. Thus, the study of regulation
of claudin-1 in hepatocytes is very important for analysis of
pathogenesis of hepatitis C virus infection.
We have been studied for the regulation of tight junction
proteins including claudin-1 in hepatocytes in vivo and in
vitro. In this lecture, we present the regulation in expression
and function of hepatic claudin-1 by growth factors (EGF,
TGF-beta), cytokines (IL-1beta, oncostatin M) and partial
hepatectomy via distinct signal transduction pathways.
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The hepatitis C virus alternate reading frame protein
(ARFP/F) of the 1b genotype is a double-frameshift product
of the HCV core protein. In order to assess the presence
of anti-F speciﬁc antibodies and their clinical relevance in
sera of HCV patients, we produced recombinant F protein
and core protein of the 1b genotype in Escherichia coli. An
ELISA assay was developed using puriﬁed recombinant HCV
core, F protein, as well as a 99 residue synthetic F peptide.
Sera-prevalence of anti-core, anti-F and anti-F99 peptide
was 95%, 68% and 36% respectively in 168 HCV patients.
The prevalence of anti-F antibodies did not correlate with
viral load, genotypes, or ALT level. Interferon combination
therapy induced a decline of the level of anti-F antibodies in
55 responders (p < 0.01). Thirteen responders (24%) lost their
anti-F recombinant protein antibodies and 17 (31%) lost their
anti-F synthetic peptide antibodies respectively, whereas no
decrease was observed for the 17 non-responders. These
changes were signiﬁcant between responders and non-
responders (p < 0.05). Meanwhile, no change was found in
the anti-core antibody titer of these 72 treated patients.
The percentage of anti-F protein negative patients (15/15,
100%) who obtained sustained virological response was
higher than that of the anti-F positive patients (70%,
p < 0.05). Based on these ﬁndings, HCV F protein elicits a
speciﬁc antibody response other than the anti-core protein
response. Our data also suggest that the presence and the
level of anti-F antibodies response might be inﬂuenced by
interferon plus ribavirin treatment and associated with SVR
in Chinese hepatitis C patients.
I-44 Efﬁcacy and relapse: peginterferon alpha-2a plus
ribavirin combination therapy in Chinese patients
with chronic hepatitis C in clinical practice
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Chronic hepatitis C virus (HCV) infection poses a challenge
for a growing number of infected patients who exhibit
disease complications, including cirrhosis, hepatocellular
carcinoma, and liver failure in China. The combination
treatment of peginterferon alpha (PEG-IFN alpha) plus
ribavirin (RBV) is recommended as a standard care for
HCV infections, which can improves hepatic markers and
eradicates the virus in about 50% of patients. However, a
signiﬁcant number of patients do not respond to therapy or
relapse following treatment discontinuation. Several viral,
hepatic, and patient-related factors inﬂuence response to
therapy.
In our clinical practice, a total of 77 interferon-naive
patients (61% male; median age 47 years) with chronic
hepatitis C include 11 cirrhotic patients (no genotyping)
received PEG-IFN alpha-2a 180 mcg/week plus RBV
900 1200mg/day for 48 weeks and follow up 24 weeks. The
results show that the patients have more RVR and EVR rate
(54% and 90.9% respectively). While the SVR (undetectable
HCV-RNA 24 weeks after treatment completion) rate is only
51.5%
In conclusion: Comparing with the data of clinical trail, the
RVR, EVR and EOTR were higher, while SVR was the same in
Chinese patient with chronic hepatitis C patients received
the combination therapy of PEG-IFN plus RBV. The reason of
high relapse was still unknown. Although optimal duration of
retreatment and beneﬁts and safety of maintenance therapy
have not been determined, an extended duration is likely
needed, even for the patients who achieved EVR.
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I-45 Rational management of community-acquired
pneumonia
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Pneumonia is the commonest cause of fever world-wide and
accounts for considerable morbidity and mortality, and for
a large proportion of the workload for the frontline doctors.
Not all patients with community-acquired pneumonia must
be managed as inpatients. A number of prediction rules have
been developed to help clinicians to identify predictors
of poor prognosis and some are relatively easy to use.
Empirical therapy must be started as soon as possible based
on knowledge of the most likely infective organism(s) and its
likely anti-microbial sensitivity. Treatment success depends
on the accuracy of the diagnosis with a sound understanding
of the underlying microbiology. Clinical parameters should
be used to assess treatment outcome. Treatment failure
is usually due to incorrect diagnosis, incorrect/inadequate
therapy or development of complications.
